Changchun Genescience Pharmaceutical Co., Ltd.
Clinical trials sponsored by Changchun Genescience Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New bacterial vaginosis drug passes first safety check in healthy volunteers Results expected Sep 2026 (estimated)
- New pill could tame phenylketonuria by blocking amino acid absorption Results expected Sep 2026 (estimated)
- New injection for Graves' disease enters first human tests Results expected Oct 2026 (estimated)
- Head-to-Head: which drug tames high prolactin better? Results expected Nov 2026 (estimated)
- New growth hormone drug enters first human tests Results expected Nov 2026 (estimated)
-
Can growth hormone boost height in children with dwarfism?
Disease control CompletedThis trial is testing whether daily injections of recombinant human growth hormone can improve growth in children with achondroplasia, a genetic condition that causes short stature. The study will include children aged 2 to 10 who have not previously been treated with growth horm…
Phase 4 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control CompletedThis study tested a new drug called gentuximab combined with the chemotherapy drug paclitaxel in 76 people with advanced stomach or gastroesophageal junction cancer that had worsened after initial treatment. The goal was to find a safe and effective dose and see if the combinatio…
Phase 1/2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New injection GenSci120 takes first step toward taming autoimmune disease
Disease control CompletedThis early-phase trial tested a single injection of GenSci120 in 58 healthy adults to see if it is safe and how the body processes it. The drug aims to control the immune system, which could one day help people with autoimmune diseases. Because this is a Phase 1 study, it only lo…
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill may cool menopausal hot flashes
Symptom relief CompletedThis study tested a new tablet, GS1-144, to see if it can reduce moderate to severe hot flashes in postmenopausal women. 129 women took either the drug or a placebo for 12 weeks. The goal was to measure changes in hot flash frequency and severity, as well as quality of life.
Phase 2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Smoking may change how this drug works in postmenopausal women
Knowledge-focused CompletedThis study tests whether smoking changes how the body processes a single dose of GS1-144 tablets. It involves 24 healthy Chinese women aged 40-65 who are postmenopausal. Researchers will measure drug levels in the blood to see if smoking affects the drug's breakdown. The goal is …
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC